tbuckley/cabot-search huggingface dataset:
The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3-Mutated (FLT3mut+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study
Authors: Ellen K. Ritchie, David Cella, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, Cristina Ivanescu, Bhavik J. Pandya, Manasee V Shah
Journal: Blood (2019)
ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia
Authors: Changnian Liu, Bin Liu, Chunping Xu, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, James Zhang, Chengzhi Yu
Journal: Blood (2019)
Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization
Authors: Esin C. Namoglu, Mitchell E. Hughes, Daniel J. Landsburg, Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, James N. Gerson, Stefan K. Barta, Sunita Dwivedy Nasta
Journal: Blood (2019)
Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment
Authors: Immo Prinz, Inga Sandrock, Ulrich Mrowietz
Journal: The Journal of Experimental Medicine (2019)

The IL-17 cytokine family comprising IL-17A to IL-17F and receptor subunits IL-17RA to IL-17RE represents a genetically ancient intercellular network regulating local tissue homeostasis. Its pivotal role in antifungal defense and its central position in the pathogenesis of inflammatory diseases including psoriasis were discovered only relatively late in the early 2000s. Since the connection of dysregulated IL-17 and psoriasis pathogenesis turned out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been approved and are used as first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in clinical development.
Reply:
Authors: Kaveh Hajifathalian, Babak Torabi Sagvand, Arthur McCullough
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. We would like to respond to Dr. Braillon's comments in kind. P‐hacking refers to inappropriately selective practices in data collection and statistical analysis to achieve a false‐positive statistical result, and the fact that a study is performed with a frequently used data source has no relevance. P‐hacking includes selective recording of data, unwarranted subgroup analyses, and post hoc selection of arbitrary outcomes or covariates.1 However, our study was performed by including all the available data from National Health and Nutrition Examination Survey (NHANES) participants, with all‐cause mortality as a universally accepted main outcome and with maximum inclusion of relevant covariates for association between alcohol use and mortality based only on their availability in NHANES. The comments on the effect of confounders and use of biochemical models for diagnosis of nonalcoholic fatty liver disease (NAFLD) are already discussed in detail in our article. Dr. Braillon cites one study on poor performance of hepatic steatosis index (HSI), but even this study reports HSI to have "performed well in terms of discriminative ability for the overall population," with an area under the receiver operating characteristic curve of 0.83 for diagnosis of NAFLD.2 Categorization of alcohol use in our study is not arbitrary and is consistent with the established literature.3 As explained in the methods section of the study, alcohol use was defined using the average number of drinks per day over a period of 12 months, and the participants did not have to be daily or "continuous" drinkers. Furthermore, and consistent with current consensus guidelines, we excluded participants with significant alcohol use from the definition of NAFLD.4 The comments on epidemiology of alcohol consumption, its various health effects, and the role of the lay press and the alcohol lobby are not related to the design and findings of our study.
Memory retrieval modulates spatial tuning of single neurons in the human entorhinal cortex
Authors: Salman E. Qasim, Jonathan Miller, Cory S. Inman, Robert E. Gross, Jon T. Willie, Bradley Lega, Jui-Jui Lin, Ashwini Sharan, Chengyuan Wu, Michael R. Sperling, Sameer A. Sheth, Guy M. McKhann, Elliot H. Smith, Catherine Schevon, Joel M. Stein, Joshua Jacobs
Journal: Nature Neuroscience (2019)
Vital Considerations for Aspirin in Prevention of Preeclampsia, a Multifaceted Pregnancy Disorder—Reply
Authors: Antonis Voutetakis, Panagiota Pervanidou, Christina Kanaka-Gantenbein
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Significant Differences in Stem Cell Transplant Utilization Rates (STUR) of Autologous Hematopoietic Cell Transplant (AHCT) in Multiple Myeloma (MM) Based on Ethnicity without Differences in Efficacy. a CIBMTR Report
Authors: Jeffrey R. Schriber, Parmeswaran Hari, Kwang Woo Ahn, Mingwei Fei, Amrita Krishnan, Anita D'Souza
Journal: Blood (2016)
Detection of Glaucoma
Authors: C. N. Smyth
Journal: BMJ (1963)

MEDICALJOURNALwe have conducted a number of studies on the selenium content of teeth, placental tissue, and foetal cord blood, bovine milk, eggs, water, and human milk in relation to dental caries susceptibility in children.5-FThere is no doubt that the role played by trace elements in preventing dental caries requires further exploration.It is believed, however, that the study of trace elements that may be responsible for increasing the susceptibility to dental caries, such as selenium, should also be given serious consideration by research workers.-I am, etc.,
Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML) and Chronic Myelomonocytic Leukemia (CMML) Show Similar Clinical, Morphological, Immunophenotypic and Molecular Features
Authors: Xavier Calvo, Nieves Garcia-Gisbert, Ivonne Parraga, Lourdes Florensa, Sara Montesdeoca, Concepción Fernández, Marta Salido, Anna Puiggros, Blanca Espinet, Beatriz Bellosillo, Lluís Colomo, David Roman, Marcio Andrade, Brayan Merchan, Ana Ferrer, Leonor Arenillas
Journal: Blood (2019)
Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis
Authors: Fengjuan Fan, Stefano Malvestiti, Yujia Shen, Eugenio Morelli, Yuji Mishima, Anja Seckinger, Dirk Hose, Latifa Bakiri, Sonia Vallet, Martin Sattler, Aldo M. Roccaro, Hartmut Goldschmidt, Martin Percherstorfer, Chunyan Sun, Yu Hu, Erwin F Wagner, Piefrancesco Tassone, Irene M. Ghobrial, Dirk Jaeger, Klaus Podar
Journal: Blood (2019)
The Adherence to MRD Time Points Is a Significantly Prognostic Predictor in an MRD-Directed Therapy for Childhood Acute Lymphoblastic Leukemia in Taiwan
Authors: Hsi-Che Liu, Ting-Chi Yeh, Tang-Her Jaing, Shih-Hsiang Chen, Chih-Cheng Hsiao, Shih-Chung Wang, Kang-Hsi Wu, Fang-Liang Huang, Shyh-Shin Chiou, Hsiu-Ju Yen, Yu-Hsiang Chang, Shu-Huey Chen, Yu-Hua Chao, Shin-Nan Cheng, Jinn-Li Wang, Rong-Long Chen, Chao-Ping Yang, Iou-Jih Hung, Jen-Yin Hou, Ting-Huan Huang, Jiunn-Ming Sheen, Yu-Chieh Chen, Ching-Tien Peng, Pei-Chin Lin, Yu-Mei Liao, Te-Kau Chang, Chien-Hui Hung, Lee-Yung Shih
Journal: Blood (2019)
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial
Authors: Paul J Bröckelmann, Annette Plütschow, Richard Greil, Josée M Zijlstra, Timothy Illidge, Alexander Fosså, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Felicitas Thol, Michael Fuchs, Andreas Engert, Christian Baues
Journal: Blood (2019)
Improvement of Survival in JMML By Induction Regimen of Decitabine + Cytarabine + Fludarabine before Hematopoietic Stem Cell Transplantation: Study of 33 Cases in Single Center
Authors: Xiaoqin Feng, Zhiyong Peng, Yuelin He, Chunfu Li, Yongsheng Ruan, Xuan Liu, Rongfang Ding, Wanxia Tan
Journal: Blood (2019)
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan
Authors: Daniel J. DeAngelo, Brian A Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani, Paula Marlton, Michael E O'Dwyer, William E. Fogler, John L. Magnani, Mary M Chen, Eric J. Feldman, Helen M Thackray, Pamela S. Becker
Journal: Blood (2019)
Platelet CD34 Expression and a Congenital Collar Bone Malformation Associated with a Partial CBFB Deletion in a Case with a Bleeding Disorder
Authors: Maaike G.J.M. van Bergen, Joline L. Saes, Annet Simons, Konnie M. Hebeda, Yvonne M.C. Henskens, Britta A.P. Laros-vanGorkom, Saskia E.M. Schols, Frank W.M.B. Preijers, Marjolijn C. Jongmans, Joop H. Jansen, Bert A. Van der Reijden
Journal: Blood (2019)
Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active
Authors: Timothy S. Pardee, Kris C Wood, Kevin H Lin, Justine Rutter, Mariaelena Pierobon, Emanuel Petricoin, Susan Lyerly, Sarah Dralle, Megan Manuel, Leslie Renee Ellis, Dianna S. Howard, Rupali Bhave, Bayard L Powell
Journal: Blood (2019)
Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study
Authors: Giulia Benevolo, Elena Maria Elli, Roberto Latagliata, Mario Tiribelli, Florian H. Heidel, Francesco Cavazzini, Massimiliano Bonifacio, Monica Crugnola, Gianni Binotto, Alessandra D'Addio, Alessia Tieghi, Micaela Bergamaschi, Giovanni Caocci, Nicola Polverelli, Elisa Diral, Eloise Beggiato, Giuseppe Auteri, Lucia Catani, Emanuele Sutto, Davide Griguolo, Katia Codeluppi, Ida Carmosino, Antonio Cuneo, Gianpietro Semenzato, Mauro Krampera, Francesco Lanza, Roberto Massimo Lemoli, Michele Cavo, Daniela Bartoletti, Massimo Breccia, Giuseppe A. Palumbo, Nicola Vianelli, Francesca Palandri
Journal: Blood (2019)
PATH-12. IDENTIFYING MOLECULAR PROGNOSTIC MARKERS IN IDHwt GLIOBLASTOMA
Authors: Iyad Alnahhas, Pierre Giglio, Javier Gonzalez, Vinay Puduvalli
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Despite our deeper understanding of the genomic alterations associated with glioblastoma (GBM), only a few genetic and epigenetic modifications have been proven to be meaningful in clinical practice. We have identified molecular parameters of prognostic relevance in IDHwt GBM using patient data from the Ohio State University (OSU) and the publicly available MSK-IMPACT database. METHODS A clinically annotated database of glioma patients at OSU- whose tumors were analyzed through Foundation One genomic testing- was utilized to examine mutation and copy number variation (CNV) data. 73 patients with IDHwt GBM were included in this study cohort along with 200 similar patients from the MSK-IMPACT cohort. Data from the MSKCC group was extracted from the cBioPortal database. Altered genes were correlated with clinical outcomes using Cox proportional hazards models. Univariate and multivariate analyses were applied, and variables included: MDM/P53, CDKN2A/B, CDK/CCND, RB1, EGFR/ ERBB, FGFR, PDGFR/KIT, NF1, PI3K, PI3K class 2, MYC and TERT promoter mutations. RESULTS Using univariate and multivariate analyses, EGFR activating alterations (amplification, mutations) and RB1 alterations (deletion, mutations) showed significant correlation with favorable outcome in IDHwt GBM: HR 0.496 for EGFR (p&lt; 0.0001) and 0.454 for RB1 (p=0.025). Furthermore, the presence of PDGFR alterations, in EGFR altered tumors only, carried a significantly worse survival in univariate and multivariate analyses: HR 5.094 (p=0.004). This suggests an interaction between EGFR and PDGFR that could be of therapeutic relevance. CONCLUSIONS We found that GBM tumors harboring EGFR and/or RB1 alterations have better survival compared to tumors that are EGFR/RB1 wild-type. Moreover, PDGFR alterations worsens survival in EGFR altered GBM. This data provides further insights that might guide targeted therapies in IDHwt GBM.
NIMG-31. BRAIN CONNECTIVITY PATTERNS CHARACTERIZE COGNITIVE IMPAIRMENT IN LONG-TERM SURVIVORS OF LOW-GRADE GLIOMA (LGG) USING RESTING-STATE FUNCTIONAL MRI (rs-fMRI)
Authors: Chencai Wang, Kathleen Van Dyk, Catalina Raymond, Brandon F Heimberg, Justin Choi, Albert Lai, Timothy Cloughesy, P Leia Nghiemphu, Benjamin Ellingson
Journal: Neuro-Oncology (2019)

Abstract Advanced multimodality treatments that have led to longer survival rates for patients with low-grade gliomas (LGGs) have also resulted in significant changes in cognition and quality of life (QoL). These changes remain poorly understood, largely due to the lack of multifactorial and in-depth studies on cognitive impairment in patients with LGG. Resting-state functional MRI (rs-fMRI) has been widely used as a reliable imaging biomarker to evaluate the treatment outcome by characterizing the cerebral networking alteration associated with a patient’s neurological status. In this preliminary report of an active study, we investigated the cognitive function and cerebral networking connectivity via rs-fMRI in survivors who had completed treatment for LGG within the past 10 years. Survivors were administered a battery of standardized neuropsychological tests. Of the 20 participants enrolled to date (mean age 43 ± 11), 10 participants were categorized as cognitively impaired based on the International Cognition and Cancer Task Force (ICCTF) guidelines, with recommended adjustments considering the number of tests in the battery. Compared to cognitively unimpaired participants, functional connectivity in cognitively impaired patients was lower between memory, visuospatial processing, and primary sensorimotor regions. These preliminary observations suggest there is a potential link between overall cognitive impairment and functional connectivity of various networks as measured using resting-state fMRI.
Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?
Authors: Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Onder Arslan, Muhit Özcan, Taner Demirer, Gunhan Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Pervin Topcuoglu
Journal: Blood (2019)
A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia
Authors: Haydar Celik, Katherine E. Lindblad, Bogdan Popescu, Giovanna Fantoni, Gege Gui, Janet Valdez, Meghali Goswami, Christin Destefano, Catherine E. Lai, Angélique Biancotto, Julián Candia, Foo Cheung, Julie Thompson, Jack Y. Ghannam, Gauthaman Sukumar, Richard H. Smith, Clifton L. Dalgard, Andre Larochelle, Laura Dillon, Christopher S. Hourigan
Journal: Blood (2019)
Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy
Authors: Akihiko Sawaki, Kana Miyazaki, Toshifumi Takeuchi, Kyoko Kobayashi, Hiroshi Imai, Isao Tawara, Ryoichi Ono, Tetsuya Nosaka, Motoko Yamaguchi, Naoyuki Katayama
Journal: Blood (2019)
Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation
Authors: Alison M Boyce, Michael T Collins
Journal: Endocrine Reviews (2019)

Abstract Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare disorder of striking complexity. It arises from somatic, gain-of-function mutations in GNAS, leading to mosaic Gα s activation and inappropriate production of intracellular cyclic adenosine monophosphate (cAMP). The clinical phenotype is largely determined by the location and extent of affected tissues, and the pathophysiological effects of Gα s activation within these tissues. In bone, Gα s activation results in impaired differentiation of skeletal stem cells, leading to discrete skeletal lesions prone to fracture, deformity, and pain. Extraskeletal manifestations include a variable combination of hyperpigmented macules and hyperfunctioning endocrinopathies. Distinctive age-related changes in disease development has key effects on histologic, radiographic, and clinical features. FD/MAS thus presents along a uniquely broad clinical spectrum, and the resulting challenges in diagnosis and management can be difficult for clinicians. This review presents FD/MAS in the context of a mosaic disorder of Gα s activation, providing an intellectual framework within which to understand, evaluate, and treat this interesting disease. It includes a comprehensive summary of current understanding of FD/MAS pathogenesis, and a detailed discussion of clinical presentation and management. Critical areas of unmet need are highlighted, including discussion of key challenges and potential solutions to advance research and clinical care in FD/MAS.
A Standardized Clinical Flow Adhesion Assay of Whole Blood Adhesion to VCAM-1 Predicts Severe SCD Phenotypes in a 2-Yr Prospective Observational Follow-up of the Original Elipsis Cohort
Authors: Patrick C. Hines, Ahmar Urooj Zaidi, Xiufeng Gao, Ke Liu, Muhammad O. Shareef, Michael Callaghan, Jennell White
Journal: Blood (2019)
PATH-27. GIANT CELL GLIOBLASTOMA DOES NOT REPRESENT A DISTINCT TUMOUR ENTITY BUT STRATIFIES INTO DIFFERENT GENETICALLY DEFINED SUBTYPES
Authors: Anna Wiedey, Evelyn Dörner, Anja zur Mühlen, Maria de Azevedo Pinto, Christof Kramm, Andreas Waha, Torsten Pietsch
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Giant cell glioblastoma (G-GBM) is a rare variant of glioblastoma (GBM) characterized by large often multinucleated tumour cells. G-GBM occurs most frequently de novo; in contrast to IDH wildtype GBM they carry TP53 mutations in high frequency. METHODS We collected 58 G-GBM from 25 children and 33 adults diagnosed at the Brain Tumor Reference Center of the German Society of Neuropathology and Neuroanatomy (DGNN) in Bonn, and performed a systematic histological, immunohistochemical and genetic analysis by molecular inversion probe array assay, panel next generation sequencing and pyrosequencing. RESULTS 78.4% of G-GBM carried mutations of TP53. Five G-GBM represented IDH-mutated gliomas, 5 cases had H3F3A-G34, and 3 had H3-K27M mutations. The vast majority (75%) lacked IDH or histone gene mutations. In these, chromosome 7 showed a copy number gain in 2/3 of the cases in contrast to the other molecular types. TERT promotor mutations occurred only in adult patients at a frequency of 35.5%. Similarly, chromosome 1q gain, 10 and 13 loss was more frequent in tumours of adult patients. MGMT promotor was methylated in 30.6 % of G-GBM. As a potential therapeutic target, PDGFR-alpha was found expressed in the vast majority of cases and its gene showed copy number gain in 34.5%. CONCLUSIONS In summary, G-GBM is a histological phenotype most likely related to p53 dysfunction but can occur in different genetically defined GBM entities (IDH-, histone gene mutated or in IDH/histone wildtype GBM). (supported by grants from the Deutsche Kinderkrebsstiftung and the Medical Faculty of the University of Bonn, BONFOR)
Lenalidomide and CC-4047 Inhibit the Proliferation of Namalwa Cancer Cells While Expanding CD34+ Progenitor Cells. New Insights on the Combination Therapy with Certain HDAC Inhibitors for Hematological Cancers.
Authors: Dominique Verhelle, Laura G. Corral, Kevin Wong, Jessica H. Mueller, Laure Moutouh de Parseval, Kristen Jensen-Pergakes, Emilia Glezer, Gregory D. Ferguson, Helen A. Brady
Journal: Blood (2006)
Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
Authors: Marshall McKenna, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, Noa Biran, David H. Vesole, Stuart L. Goldberg, Themba Nyirenda, Andrew L. Pecora, Andre Goy, Michele L. Donato
Journal: Blood (2019)
Impact of KIR/HLA Incompatibilities after Posttransplant Cyclophosphamide Based T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation
Authors: Sarah Lindner, Tobias Berg, Christian Seidel, Franziska Kalensee, Michael A. Rieger, Hubert Serve, Gesine Bug, Joachim Schwaeble, Evelyn Ullrich
Journal: Blood (2019)
Distinct Bone Marrow Microenvironment Abnormalities in MDS and MPN with Fibrosis
Authors: Cao Sy Luan, Yoshiaki Takahoko, Hidekazu Nishikii, Naoshi Obara, Tatsuhiro Sakamoto, Takayasu Kato, Keiichiro Hattori, Ryota Matsuoka, Shingo Sakashita, Yasuhito Nannya, Hideki Makishima, Mamiko Sakata-Yanagimoto, Seishi Ogawa, Shigeru Chiba
Journal: Blood (2019)
Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas
Authors: Anthony Tarabay, Jean-Marie Michot, Anne Aupérin, Julien Lazarovici, Julien Rossignol, David Ghez, Peggy Dartigues-Cuillères, Veronique Vergé, Vincent Ribrag, Christophe Massard, Valérie Camara-clayette
Journal: Blood (2019)
Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy
Authors: Takuji Yamauchi, Kohta Miyawaki, Yuichiro Semba, Fumihiko Nakao, Takeshi Sugio, Kensuke Sasaki, Jumpei Nogami, Matthew C. Canver, Simon Osborne, Luca Pinello, Deborah Taylor, Daniel E. Bauer, Koichi Akashi, Takahiro Maeda
Journal: Blood (2019)
Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML
Authors: Agnès Guerci, Emilie Cayssials, Philippe Rousselot, Francoise Huguet, Valerie Coiteux, Marc G. Berger, Gabriel Etienne, Ali G Turhan
Journal: Blood (2019)